NF-κB Activating Scaffold Proteins as Signaling Molecules and Putative Therapeutic Targets
Authors: Chariot, A.; Meuwis, M-A.; Bonif, M.; Leonardi, A.; Merville, M-P.; Gielen, J.; Piette, J.; Siebenlist, U.; Bours, V.
Source: Current Medicinal Chemistry, Volume 10, Number 7, April 2003 , pp. 593-602(10)
Publisher: Bentham Science Publishers
Activation of transcription factors such as NF-κB occurs through signaling pathways involving sequential phosphorylation of a variety of substrates by distinct kinases. Proper assemby and activation of these kinases require interaction with non-enzymatic and essential partners named scaffold proteins. Here, we describe how the NF-κB activating scaffold proteins involved in the signaling pathways triggered by the proinflammatory cytokines TNFα, IL-1β and by the CD40 ligand play such roles. We also illustrate the human genetic diseases that are linked to mutations affecting genes coding for these proteins. We suggest that these scaffold proteins may be specifically targeted by novel therapeutical agents for the treatment of inflammation or cancers.
Document Type: Review Article
Publication date: April 1, 2003
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.